PL3618848T3 - Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne - Google Patents
Biologicznie aktywne kompleksy i ich zastosowania terapeutyczneInfo
- Publication number
- PL3618848T3 PL3618848T3 PL18729327T PL18729327T PL3618848T3 PL 3618848 T3 PL3618848 T3 PL 3618848T3 PL 18729327 T PL18729327 T PL 18729327T PL 18729327 T PL18729327 T PL 18729327T PL 3618848 T3 PL3618848 T3 PL 3618848T3
- Authority
- PL
- Poland
- Prior art keywords
- biologically active
- therapeutic applications
- active complexes
- complexes
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1707715.7A GB201707715D0 (en) | 2017-05-14 | 2017-05-14 | Preperation of biologically active complexes |
| PCT/EP2018/062396 WO2018210759A1 (en) | 2017-05-14 | 2018-05-14 | Preparation of biologically active complexes |
| EP18729327.9A EP3618848B1 (en) | 2017-05-14 | 2018-05-14 | Biologically active complexes and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3618848T3 true PL3618848T3 (pl) | 2021-06-14 |
Family
ID=59201543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20208669.0T PL3811967T3 (pl) | 2017-05-14 | 2018-05-14 | Wytwarzanie biologicznie aktywnych kompleksów |
| PL18729327T PL3618848T3 (pl) | 2017-05-14 | 2018-05-14 | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20208669.0T PL3811967T3 (pl) | 2017-05-14 | 2018-05-14 | Wytwarzanie biologicznie aktywnych kompleksów |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200140481A1 (pl) |
| EP (2) | EP3811967B1 (pl) |
| JP (2) | JP7672122B2 (pl) |
| KR (2) | KR20200015557A (pl) |
| CN (2) | CN119700935A (pl) |
| AU (1) | AU2018269304B2 (pl) |
| CA (1) | CA3063285A1 (pl) |
| DK (2) | DK3618848T3 (pl) |
| ES (2) | ES2973290T3 (pl) |
| FI (1) | FI3811967T3 (pl) |
| GB (1) | GB201707715D0 (pl) |
| PL (2) | PL3811967T3 (pl) |
| WO (1) | WO2018210759A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201621752D0 (en) * | 2016-12-20 | 2017-02-01 | Hamlet Pharma Ab | Therapeutically active complexes |
| GB201707715D0 (en) * | 2017-05-14 | 2017-06-28 | Hamlet Pharma Ab | Preperation of biologically active complexes |
| GB2574845A (en) * | 2018-06-20 | 2019-12-25 | Hamlet Pharma Ab | Therapeutically active complexes |
| WO2019243547A1 (en) * | 2018-06-20 | 2019-12-26 | Hamlet Pharma Ab | Therapeutically active complexes |
| WO2021032807A1 (en) * | 2019-08-20 | 2021-02-25 | Hamlet Pharma Ab | Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy |
| GB202015836D0 (en) * | 2020-10-06 | 2020-11-18 | Hamlet Pharma Ab | Compositions |
| WO2024075003A1 (en) | 2022-10-03 | 2024-04-11 | Linnane Pharma Ab | A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer |
| GB202303177D0 (en) | 2023-03-03 | 2023-04-19 | Linnane Pharma Ab | Method of predicting response to treatment |
| WO2025186107A1 (en) | 2024-03-04 | 2025-09-12 | Linnane Pharma Ab | Therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537273A1 (en) * | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| CN102348721A (zh) | 2009-01-09 | 2012-02-08 | 哈姆雷特药品Ab | 复合物和生产过程 |
| WO2010131237A1 (en) | 2009-05-13 | 2010-11-18 | Agriculture And Food Development Authority (Teagasc) | A process for producing a biologically active globular protein complex |
| GB0908279D0 (en) | 2009-05-14 | 2009-06-24 | Enovate Systems Ltd | Subsea winch |
| DK2643010T3 (en) * | 2010-11-24 | 2017-02-27 | Hamlet Pharma Ab | BIOLOGICAL ACTIVE COMPLEX AND ITS PREPARATION |
| ES2844874T3 (es) * | 2012-08-09 | 2021-07-23 | Hamlet Pharma Ab | Complejo de proteína de leche y ácido graso |
| GB201621752D0 (en) * | 2016-12-20 | 2017-02-01 | Hamlet Pharma Ab | Therapeutically active complexes |
| GB201707715D0 (en) | 2017-05-14 | 2017-06-28 | Hamlet Pharma Ab | Preperation of biologically active complexes |
-
2017
- 2017-05-14 GB GBGB1707715.7A patent/GB201707715D0/en not_active Ceased
-
2018
- 2018-05-14 FI FIEP20208669.0T patent/FI3811967T3/fi active
- 2018-05-14 DK DK18729327.9T patent/DK3618848T3/da active
- 2018-05-14 WO PCT/EP2018/062396 patent/WO2018210759A1/en not_active Ceased
- 2018-05-14 KR KR1020197037015A patent/KR20200015557A/ko not_active Ceased
- 2018-05-14 CN CN202411849059.8A patent/CN119700935A/zh active Pending
- 2018-05-14 ES ES20208669T patent/ES2973290T3/es active Active
- 2018-05-14 CA CA3063285A patent/CA3063285A1/en active Pending
- 2018-05-14 PL PL20208669.0T patent/PL3811967T3/pl unknown
- 2018-05-14 AU AU2018269304A patent/AU2018269304B2/en active Active
- 2018-05-14 DK DK20208669.0T patent/DK3811967T5/da active
- 2018-05-14 CN CN201880032057.6A patent/CN110650746B/zh active Active
- 2018-05-14 US US16/612,272 patent/US20200140481A1/en not_active Abandoned
- 2018-05-14 EP EP20208669.0A patent/EP3811967B1/en active Active
- 2018-05-14 JP JP2019563219A patent/JP7672122B2/ja active Active
- 2018-05-14 EP EP18729327.9A patent/EP3618848B1/en active Active
- 2018-05-14 ES ES18729327T patent/ES2861252T3/es active Active
- 2018-05-14 KR KR1020267002686A patent/KR20260021814A/ko active Pending
- 2018-05-14 PL PL18729327T patent/PL3618848T3/pl unknown
-
2021
- 2021-01-12 US US17/146,588 patent/US12331073B2/en active Active
-
2023
- 2023-03-15 JP JP2023040807A patent/JP7705160B2/ja active Active
-
2025
- 2025-05-12 US US19/205,790 patent/US20260085088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3811967T5 (da) | 2024-08-19 |
| CN110650746B (zh) | 2024-12-31 |
| ES2861252T3 (es) | 2021-10-06 |
| KR20200015557A (ko) | 2020-02-12 |
| CN119700935A (zh) | 2025-03-28 |
| US12331073B2 (en) | 2025-06-17 |
| CN110650746A (zh) | 2020-01-03 |
| WO2018210759A1 (en) | 2018-11-22 |
| PL3811967T3 (pl) | 2024-03-18 |
| KR20260021814A (ko) | 2026-02-13 |
| JP2023075290A (ja) | 2023-05-30 |
| EP3618848A1 (en) | 2020-03-11 |
| CA3063285A1 (en) | 2018-11-22 |
| EP3811967B1 (en) | 2023-12-20 |
| US20210130394A1 (en) | 2021-05-06 |
| JP7705160B2 (ja) | 2025-07-09 |
| JP7672122B2 (ja) | 2025-05-07 |
| EP3618848B1 (en) | 2020-11-25 |
| AU2018269304B2 (en) | 2025-02-27 |
| DK3618848T3 (da) | 2021-03-01 |
| ES2973290T3 (es) | 2024-06-19 |
| AU2018269304A1 (en) | 2019-11-21 |
| EP3811967A1 (en) | 2021-04-28 |
| GB201707715D0 (en) | 2017-06-28 |
| FI3811967T3 (fi) | 2023-12-28 |
| US20200140481A1 (en) | 2020-05-07 |
| JP2020519673A (ja) | 2020-07-02 |
| DK3811967T3 (da) | 2024-01-08 |
| US20260085088A1 (en) | 2026-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3618848T3 (pl) | Biologicznie aktywne kompleksy i ich zastosowania terapeutyczne | |
| IL279897A (en) | Fusosome compositions and uses thereof | |
| IL283376A (en) | Multivariate and other metal-organic frameworks, and uses thereof | |
| IL285053A (en) | Hsd17b13 variants and uses thereof | |
| EP3684365A4 (en) | PROTEIN DEGRADATION AGENTS AND USES OF SUCH | |
| PL3630917T3 (pl) | Równomiernie zamknięte nanocząstki i ich zastosowania | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| EP3709912A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| EP3565516A4 (en) | INFUSION SYSTEM AND ITS COMPONENTS | |
| DK3922279T3 (da) | Præparater til lægemiddelafgivelse og anvendelse heraf | |
| IL255228A0 (en) | Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof | |
| EP3893945A4 (en) | CROMOGLYC ESTERS AND THEIR USES | |
| EP3719050A4 (en) | COMPOUND, AND PELLET | |
| DK3514153T3 (da) | Pyrimidinforbindelse og farmaceutisk anvendelse deraf | |
| EP3580236A4 (en) | ANTI-G-CSF ANTIBODIES AND ASSOCIATED USES | |
| HUE055762T2 (hu) | Nyújtott hatású készítmények | |
| EP3526186A4 (en) | SUBSTITUTED HYDROXY STYLENE AND THEIR THERAPEUTIC APPLICATIONS | |
| PL3720875T3 (pl) | Peptydy przeciwdrobnoustrojowe i sposoby ich stosowania | |
| EP3697265A4 (en) | DISPLACEMENT AND DISCOVERY SEAT | |
| PL3986419T3 (pl) | Pochodne kwasu boronowego i ich zastosowania terapeutyczne | |
| EP3672387C0 (en) | AGRICULTURAL TILLING SET AND COMPONENTS | |
| MA50358A (fr) | Sémaglutide en thérapie médicale | |
| EP3558450A4 (en) | NEUROSTIMULATORS AND STIMULATION SYSTEMS | |
| DK3512544T3 (da) | Peptidforbindelser og terapeutiske anvendelser deraf |